✦ LIBER ✦

Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?

✍ Scribed by Philippe Aftimos; Ahmad Awada

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Minimal clinical benefit of single agent

✍ Silwan Chedid; Edgardo Rivera; Debbie K. Frye; Nuhad Ibrahim; Francisco Esteva; 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 200 KB

Phase III Trials of Eribulin Mesylate (E

✍ Chris Twelves; Javier Cortes; Linda T. Vahdat; Jantien Wanders; Corina Akerele; 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 200 KB

Developing a prediction model for benefi

✍ E Amir, OC Freedman, S Chia, T Petrella, S Dent, K Tonkin… 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 461 KB

5061 Gemcitabine and carboplatin in heav

✍ G. Natoli; F. Nelli; L. Moscetti; G. D'Auria; C. Signorelli; M.G. Chilelli; D. P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

PO67 CLINICAL BENEFIT OF ETHINYLESTRADIO

✍ Iwase, Hirotaka; Kondo, Naoto; Yamashita, Toshinari; Nakamura, Seigo; Ikeda, Mas 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Predictive factors for efficacy of capec

✍ Tomo Osako; Yoshinori Ito; Masaru Ushijima; Shunji Takahashi; Nahomi Tokudome; T 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 303 KB